[go: up one dir, main page]

BRPI0810384A2 - Terapia enzimática anticâncer - Google Patents

Terapia enzimática anticâncer

Info

Publication number
BRPI0810384A2
BRPI0810384A2 BRPI0810384-4A2A BRPI0810384A BRPI0810384A2 BR PI0810384 A2 BRPI0810384 A2 BR PI0810384A2 BR PI0810384 A BRPI0810384 A BR PI0810384A BR PI0810384 A2 BRPI0810384 A2 BR PI0810384A2
Authority
BR
Brazil
Prior art keywords
antichane
enzymatic therapy
enzymatic
therapy
antichane enzymatic
Prior art date
Application number
BRPI0810384-4A2A
Other languages
English (en)
Inventor
David R Filpula
Puja Sapra
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Publication of BRPI0810384A2 publication Critical patent/BRPI0810384A2/pt
Publication of BRPI0810384B1 publication Critical patent/BRPI0810384B1/pt
Publication of BRPI0810384B8 publication Critical patent/BRPI0810384B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0810384A 2007-04-20 2008-04-18 terapia enzimática anticâncer BRPI0810384B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91303907P 2007-04-20 2007-04-20
US60/913,039 2007-04-20
PCT/US2008/060733 WO2008131163A1 (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy

Publications (3)

Publication Number Publication Date
BRPI0810384A2 true BRPI0810384A2 (pt) 2014-11-04
BRPI0810384B1 BRPI0810384B1 (pt) 2021-02-02
BRPI0810384B8 BRPI0810384B8 (pt) 2021-05-25

Family

ID=39875909

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810384A BRPI0810384B8 (pt) 2007-04-20 2008-04-18 terapia enzimática anticâncer

Country Status (19)

Country Link
US (1) US8741283B2 (pt)
EP (1) EP2147122B1 (pt)
JP (1) JP5595904B2 (pt)
KR (1) KR101540296B1 (pt)
CN (1) CN101680039B (pt)
BR (1) BRPI0810384B8 (pt)
CA (1) CA2684749C (pt)
CY (1) CY1117000T1 (pt)
DK (1) DK2147122T3 (pt)
ES (1) ES2507508T3 (pt)
HR (1) HRP20140947T1 (pt)
IL (1) IL201593A (pt)
MX (1) MX2009011320A (pt)
NZ (1) NZ580980A (pt)
PL (1) PL2147122T3 (pt)
PT (1) PT2147122E (pt)
SI (1) SI2147122T1 (pt)
TW (1) TWI486169B (pt)
WO (1) WO2008131163A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519606A (ja) 2004-11-12 2008-06-12 アンビオン インコーポレーティッド ｍｉＲＮＡおよびｍｉＲＮＡ阻害分子に関する方法および組成物
NZ580981A (en) 2007-04-20 2012-02-24 Sigma Tau Rare Diseases S A Stable recombinant adenosine deaminase
WO2012106591A1 (en) * 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
EP3207130B1 (en) 2014-10-14 2019-08-07 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US10874724B2 (en) * 2015-05-22 2020-12-29 University Of Houston System Enzymatic immunomodulation of solid tumors and uses thereof
US20190343935A1 (en) * 2016-03-11 2019-11-14 University Of Louisville Research Foundation, Inc. Methods and compositions for treating tumors
EP3610000A1 (en) 2017-04-13 2020-02-19 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
JP2022512766A (ja) 2018-10-17 2022-02-07 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US20250075196A1 (en) * 2021-11-12 2025-03-06 Georgia Tech Research Corporation Adenosine deaminase 1 compositions and methods for using same

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346823A (en) * 1984-05-29 1994-09-13 Genencor, Inc. Subtilisin modifications to enhance oxidative stability
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5756593A (en) * 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
JP4465109B2 (ja) * 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6251382B1 (en) * 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6824766B2 (en) * 1998-04-17 2004-11-30 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6333396B1 (en) * 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US20020088017A1 (en) * 1999-04-28 2002-07-04 Board Of Regents, The University Of Texas System Adenosine deaminase deficient transgenic mice and methods for the use thereof
US6579857B1 (en) * 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
AU7868400A (en) 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery
WO2002074960A2 (en) 2000-11-08 2002-09-26 Millennium Pharmaceuticals, Inc. 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
WO2003045436A1 (en) 2001-11-28 2003-06-05 Biopolymed Inc. Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
AU2002356962C1 (en) 2001-12-12 2008-05-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US7122189B2 (en) * 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7413738B2 (en) * 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US20040175804A1 (en) * 2003-03-04 2004-09-09 Skonezny Paul M. Process for preparing dideoxyinosine using adenosine deaminase enzyme
US7301003B2 (en) * 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US7601798B2 (en) * 2005-10-04 2009-10-13 Enzon Pharmaceuticals, Inc. Methods of preparing polymers having terminal amine groups using protected amine salts
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
WO2007149686A2 (en) 2006-06-21 2007-12-27 Enzon Pharmaceuticals, Inc. Stabilized proteins
AU2007296189A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polyalkylene oxides having hindered ester-based biodegradable linkers
US20080159964A1 (en) * 2006-12-29 2008-07-03 Enzon Pharmaceuticals, Inc. Use of adenosine deaminase for treating pulmonary disease
NZ580981A (en) 2007-04-20 2012-02-24 Sigma Tau Rare Diseases S A Stable recombinant adenosine deaminase

Also Published As

Publication number Publication date
CN101680039B (zh) 2016-08-24
KR20090130108A (ko) 2009-12-17
EP2147122B1 (en) 2014-07-16
WO2008131163A1 (en) 2008-10-30
IL201593A0 (en) 2010-05-31
ES2507508T3 (es) 2014-10-15
IL201593A (en) 2017-07-31
MX2009011320A (es) 2009-12-15
DK2147122T3 (da) 2014-10-13
CA2684749C (en) 2016-06-21
HRP20140947T1 (hr) 2015-02-13
JP2010524968A (ja) 2010-07-22
US8741283B2 (en) 2014-06-03
TWI486169B (zh) 2015-06-01
CA2684749A1 (en) 2008-10-30
SI2147122T1 (sl) 2015-01-30
KR101540296B1 (ko) 2015-07-31
US20090047270A1 (en) 2009-02-19
RU2009142817A (ru) 2011-05-27
PT2147122E (pt) 2014-10-15
TW200902051A (en) 2009-01-16
AU2008242791A1 (en) 2008-10-30
JP5595904B2 (ja) 2014-09-24
NZ580980A (en) 2012-04-27
WO2008131163A8 (en) 2010-01-28
PL2147122T3 (pl) 2015-05-29
BRPI0810384B1 (pt) 2021-02-02
CN101680039A (zh) 2010-03-24
BRPI0810384B8 (pt) 2021-05-25
EP2147122A1 (en) 2010-01-27
CY1117000T1 (el) 2017-04-05
EP2147122A4 (en) 2010-11-17

Similar Documents

Publication Publication Date Title
BRPI0821573A2 (pt) benzofuropirimidonas
HRP20170963T1 (hr) Modificirani saharidi
ATE501136T1 (de) Imidazopyridinone
BRPI0916931A2 (pt) agentes terapêuticos
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
EP2052011A4 (en) TARGETED THERAPEUTIC AGENT POLYLYSIN DENDRIMER
DK2035369T3 (da) Terapeutiske
DK2219683T3 (da) Målrettet radioterapi
DK2144905T3 (da) Terapeutiske midler
BRPI0814519A2 (pt) Organopolissiloxano
BRPI0811451A2 (pt) Exopolissacarídeo
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
BRPI0812840A2 (pt) 2-imidazolinas
BRPI0810384A2 (pt) Terapia enzimática anticâncer
DK2173831T3 (da) Brøndbehandling
BRPI0815203A2 (pt) gel contendo pirfenidona
AT505058A3 (de) Türschliesssystem
BRPI0814310A2 (pt) Enzima lecitina-colesterol acetiltransferase modificada
BRPI0920743A2 (pt) ribonucleases terapeuticas
LT3150178T (lt) Stimuliavimo aparatas
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI0818598A2 (pt) agentes terapêuticos - 802
EP2146744A4 (en) THERAPEUTIC BETA-GLUCAN COMPOSITIONS
DE112008001216A5 (de) Magnetronplasmaanlage
EP2192402A4 (en) Enzyme electrode

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: DEFIANTE FARMACEUTICA, S.A. (PT)

B25A Requested transfer of rights approved

Owner name: SIGMA-TAU RARE DISEASES, S.A. (PT)

B25A Requested transfer of rights approved

Owner name: SIGMA-TAU PHARMA LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: SIGMA-TAU RARE DISEASE LTD. (GB)

B25D Requested change of name of applicant approved

Owner name: LEADIANT BIOSCIENCES LIMITED (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: UNIKERIS LIMITED (GB)